Effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV with historical drug resistance mutations

To the Editor: China provides free antiretroviral therapy (ART) for people with human immunodeficiency virus (HIV), typically using two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI). Variables Total Age (years) 37 (33–47) Gender Ma...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2024-11, Vol.137 (22), p.2758-2760
Main Authors: Chang, Ziwei, Zhu, Hongyan, Zhang, Yiting, Chen, Yaling, Li, Jiahui, Qin, Jiamin, Zhu, Yueping, Wei, Hongxia, Yang, Yongfeng, Zou, Meiyin, Qian, Feng, Hu, Zhiliang
Format: Article
Language:English
Subjects:
Correspondence
Drug resistance
Drug therapy
HIV
Human immunodeficiency virus
Immune system
Mutation
Patients
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To the Editor: China provides free antiretroviral therapy (ART) for people with human immunodeficiency virus (HIV), typically using two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI). Variables Total Age (years) 37 (33–47) Gender Male 60 (96.8) Female 2 (3.2) HIV risk factor Homosexual 44 (72.1) Heterosexual 14 (23.0) Transfusion 2 (3.2) Others 2 (3.2) Time on virological suppression before switch (months) 40 (29–63) Initial ART regimens 3TC/TDF 47 (75.8) 3TC/AZT 13 (21.0) NVP 14 (22.6) EFV 45 (72.6) Last antiretroviral regimens before switch 3TC/ (TDF or TAF) 26 (41.9) 3TC/AZT 25 (40.3) DTG 21 (33.9) LPV/r 50 (80.6) CD4 cell count at switch (cells/µL) 426 (305–584)
ISSN:0366-6999
2542-5641
2542-5641
DOI:10.1097/CM9.0000000000003317